Dergiler / Turkish Journal of Pharmaceutical Sciences / 2019 / Cilt: 16 - Sayı: 4

Some New Hydrazone Derivatives Bearing the 1,2,4-Triazole Moiety as Potential Antimycobacterial Agents

Antimikobakteriyel Etki Göstermesi Beklenen Yeni Bazı 1,2,4-Triazol Yapısı Taşıyan Hidrazon Türevleri

Sayfa
432–436
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The antimycobacterial activities of the compoundswere determined in vitro against Mycobacterium tuberculosis H37Rv.Results: The biological assay results showed that the methylsulfonyl-substituted derivative 2f displayed the highest antimycobacterial activity inthis series.Conclusion: Although the methylsulfonyl-substituted derivative exhibited significant antimycobacterial activity, none of the synthesized compoundswas as effective as isoniazid, rifampin, ethambutol, and ciprofloxacin against M. tuberculosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: The aim of this study was to synthesize, characterize, and screen some new 1-(4-((2-(4-substitutedphenyl)hydrazono)methyl)phenyl)-1H-1,2,4-triazole derivatives for their antimycobacterial activities.Materials and Methods: The target compounds (2a-h) were gained by condensation of 4-(1H-1,2,4-triazol-1-yl)benzaldehyde with appropriatephenylhydrazines.
📊
Temel Bulgular & Veri:Their structures were elucidated by IR, 1H-NMR, and mass spectrometry.
💡
Sonuç & Katkı:The antimycobacterial activities of the compoundswere determined in vitro against Mycobacterium tuberculosis H37Rv.Results: The biological assay results showed that the methylsulfonyl-substituted derivative 2f displayed the highest antimycobacterial activity inthis series.Conclusion: Although the methylsulfonyl-substituted derivative exhibited significant antimycobacterial activity, none of the synthesized compoundswas as effective as isoniazid, rifampin, ethambutol, and ciprofloxacin against M. tuberculosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: The aim of this study was to synthesize, characterize, and screen some new 1-(4-((2-(4-substitutedphenyl)hydrazono)methyl)phenyl)-1H-1,2,4-triazole derivatives for their antimycobacterial activities.Materials and Methods: The target compounds (2a-h) were gained by condensation of 4-(1H-1,2,4-triazol-1-yl)benzaldehyde with appropriatephenylhydrazines. Their structures were elucidated by IR, 1H-NMR, and mass spectrometry. The antimycobacterial activities of the compoundswere determined in vitro against Mycobacterium tuberculosis H37Rv.Results: The biological assay results showed that the methylsulfonyl-substituted derivative 2f displayed the highest antimycobacterial activity inthis series.Conclusion: Although the methylsulfonyl-substituted derivative exhibited significant antimycobacterial activity, none of the synthesized compoundswas as effective as isoniazid, rifampin, ethambutol, and ciprofloxacin against M. tuberculosis.

Abstract

Amaç: Bu çalışma, 1-(4-((2-(4-sübstitüefenil)hidrazono)metil)fenil)-1H-1,2,4-triazol türevlerinin sentezlerini yaparak yapılarını aydınlatmayı ve antimikobakteriyel aktivitelerini incelemeyi amaçlamaktadır. Gereç ve Yöntemler: Bu çalışmada hedef bileşikler (2a-h), 4-(1H-1,2,4-triazol-l-il)benzaldehidin uygun fenilhidrazinlerle kondenzasyonu ile elde edilmiştir. Bileşiklerin yapıları, IR, 1H-NMR ve kütle spektrometrisi ile aydınlatılmıştır. Antimikobakteriyel aktiviteleri, Mycobacterium tuberculosis H37Rv’ye karşı in vitro olarak incelenmiştir. Bulgular: Aktivite sonuçları incelendiğinde, metilsülfonil sübstitüe türevin 2f serinin en aktif üyesi olduğu bulunmuştur. Sonuç: Metilsulfonil sübstitüe türevin dikkate değer antimikobakteriyel aktivite göstermesine rağmen, sentezlenen bileşiklerin hiçbirinin M. tuberculosis’e karşı izoniazit, rifampin, etambutol ve siprofloksazin kadar etkili olmadıkları bulunmuştur.

🔖

Bu Makaleye Atıf Yap

SARI, K. Ö., TAN, O. Ü., SRIRAM, D., BALKAN, A. (2019). Some New Hydrazone Derivatives Bearing the 1,2,4-Triazole Moiety as Potential Antimycobacterial Agents. Turkish Journal of Pharmaceutical Sciences, Cilt: 16 - Sayı: 4, 432–436. https://ajindex.com/articles/404081

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Zhenkun MA, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010;375:2100-2109
  2. World Health Organization (WHO) – Global Tuberculosis Report 2017. Available at
  3. Saltini C. Chemotherapy and diagnosis of tuberculosis. Respir Med. 2006;100:2085-2097
  4. Tiberi S, Scardigli A, Centis R, D’Ambrosio L, Muñoz-Torrico M, SalazarLezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, Caminero Luna JA. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 2017;56:181-184
  5. Hoagland DT, Liu J, Lee RB, Lee RE. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016;102:55-72
  6. Ahmad S, Mokaddas E. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. J Infect Public Health. 2014;7:75-91
  7. Franke MF, Becerra MC, Tierney DB, Rich ML, Bonilla C, Bayona J, McLaughlin MM, Mitnick CD. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc. 2015;12:674-679
  8. Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19:517-524
  9. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692
  10. Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A. Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis. 2016;16:e34-e46
  11. Jones D. Tuberculosis success. Nat Rev Drug Discov. 2013;12:175-176
  12. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J. 2013;41:1393-1400
  13. Kumar K, Abubakar I. Clinical implications of the global multidrug-resistant tuberculosis epidemic. Clin Med (Northfield Il). 2015;15(Suppl6):s37-s42
  14. Cochrane JR, White JM, Wille U, Hutton CA. Total synthesis of mycocyclosin. Org Lett. 2012;14:2402-2405
  15. Podust LM, Ou